SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-15-219327
Filing Date
2015-06-10
Accepted
2015-06-10 16:15:35
Documents
5
Period of Report
2014-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K (AMENDMENT NO. 1) d937895d10ka.htm 10-K/A 45275
2 EX-10.56 d937895dex1056.htm EX-10.56 267554
3 EX-10.59 d937895dex1059.htm EX-10.59 17525
4 EX-31.3 d937895dex313.htm EX-31.3 3059
5 EX-31.4 d937895dex314.htm EX-31.4 3122
  Complete submission text file 0001193125-15-219327.txt   337576
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-34186 | Film No.: 15923675
SIC: 2834 Pharmaceutical Preparations